Loading...
•
Sep 30, 2020
Kala Bio Q3 2020 Earnings Report
Kala Pharmaceuticals reported third-quarter financial results, highlighting FDA approval for EYSUVIS and INVELTYS net revenue.
Key Takeaways
Kala Pharmaceuticals reported a net product revenue of $2.2 million from INVELTYS sales. The company received FDA approval for EYSUVIS and anticipates shipping to wholesalers by the end of 2020. Kala expects its cash position and INVELTYS revenue to provide a runway into at least the third quarter of 2022, with EYSUVIS revenue expected to provide additional runway.
FDA approved EYSUVIS for short-term treatment of dry eye disease.
EYSUVIS is expected to begin shipping to wholesalers by the end of 2020.
INVELTYS net revenue for Q3 2020 was $2.2 million.
Cash position and INVELTYS revenue are expected to provide runway into at least Q3 2022.
Forward Guidance
Kala Pharmaceuticals anticipates that its existing cash, cash equivalents and short-term investments, along with anticipated sales of INVELTYS, will enable it to fund its operations into at least the third quarter of 2022. Kala expects revenue anticipated to be generated from sales of EYSUVIS will provide additional cash runway.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...